Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report 2025

Description

Treatment for metabolic dysfunction-associated steatohepatitis (MASH) involves both medical and lifestyle approaches that target the inflammation and liver damage caused by fat buildup in the liver, which is linked to metabolic issues such as obesity, diabetes, and insulin resistance. The goal is to improve liver function and metabolic health outcomes.

The primary treatments for MASH include medications and therapies. Drug treatments involve the use of pharmaceutical agents to reduce liver inflammation, fibrosis, and fat accumulation, aiming to enhance liver function and halt disease progression. These treatments are provided to patients through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and specialty clinics, and can be used in settings such as hospitals, homecare, and others.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market research report is one of a series of new reports from The Business Research Company that provides metabolic dysfunction-associated steatohepatitis (MASH) treatment market statistics, including metabolic dysfunction-associated steatohepatitis (MASH) treatment industry global market size, regional shares, competitors with metabolic dysfunction-associated steatohepatitis (MASH) treatment market share, detailed metabolic dysfunction-associated steatohepatitis (MASH) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic dysfunction-associated steatohepatitis (MASH) treatment industry. This metabolic dysfunction-associated steatohepatitis (MASH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size has grown exponentially in recent years. It will grow from $2.00 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 30.0%. The growth observed in the historical period can be linked to the increasing prevalence of non-alcoholic steatohepatitis, modern dietary trends that include high consumption of processed foods, sedentary lifestyles, and the rising occurrence of metabolic conditions.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size is expected to see exponential growth in the next few years. It will grow to $7.38 billion in 2029 at a compound annual growth rate (CAGR) of 29.8%. The anticipated growth during the forecast period is driven by the rising rates of obesity and obesity-related conditions, early interventions, improved reimbursement mechanisms, expanded insurance coverage, and heightened awareness of liver diseases. Key trends expected to shape this period include advancements in technology, the development of new treatments in the pipeline, strategic partnerships and collaborations, personalized medicine, precision therapeutics, and increased investment in clinical trials and research.

The growing prevalence of obesity is expected to drive the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in the future. Obesity is a condition marked by excessive body fat accumulation, which can harm overall health and is usually defined by a body mass index (BMI) of 30 or higher. The global rise in obesity is primarily attributed to factors such as sedentary lifestyles, poor dietary habits, and metabolic risks. MASH treatment in obesity aims to combat insulin resistance, reduce liver fat, and enhance metabolic health through both lifestyle modifications and targeted treatments. For example, a report from the World Heart Foundation, a Switzerland-based global cardiovascular organization, published in March 2023, highlighted that around 2.3 billion adults and children worldwide are obese or overweight, and this figure is expected to increase to 2.7 billion by 2025, reflecting the ongoing obesity trend. Consequently, the rise in obesity rates is propelling the growth of the MASH treatment market.

Major companies in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are focusing on the development of innovative products, including solutions for liver fibrosis. These treatments aim to address the root causes of liver damage, with a focus on lifestyle changes, antiviral medications, and emerging antifibrotic therapies. The goal is to prevent the progression of fibrosis, potentially reversing it, and enhancing liver function. For example, in March 2024, Madrigal Pharmaceuticals, a US-based biopharmaceutical company, received FDA approval for Rezdiffra (resmetirom). This is the first-ever treatment for MASH with moderate to severe liver fibrosis. Rezdiffra, a daily oral tablet, showed effectiveness in resolving MASH without worsening fibrosis and improving liver fibrosis in phase 3 clinical trials. This breakthrough provides a non-invasive alternative to liver biopsies, significantly improving patient access and outcomes in managing fatty liver disease.

In January 2024, Suzhou Ribo Life Science Co., Ltd., a clinical-stage company based in China, and Ribocure Pharmaceuticals AB (Ribo), a clinical-stage biotechnology company from Sweden, announced a $2 billion collaboration with Boehringer Ingelheim. This partnership aims to develop innovative treatments for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will combine Ribo's RNAi therapeutic platform with Boehringer Ingelheim's expertise in cardiovascular, renal, and metabolic diseases. The goal is to address the critical need for effective therapies that can halt the progression of NASH and restore liver function. Boehringer Ingelheim, a pharmaceutical company based in Germany, is actively working on treatments for MASH.

Major players in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, and Hepion Pharmaceuticals.

North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metabolic dysfunction-associated steatohepatitis (MASH) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market consists of revenues earned by entities by providing services such as clinical care services, nutritional counseling, pharmacotherapy management, patient education, and support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic dysfunction-associated steatohepatitis (MASH) treatment market also includes sales of antioxidants, antidiabetic drugs, and liver protective supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metabolic dysfunction-associated steatohepatitis (mash) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metabolic dysfunction-associated steatohepatitis (mash) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metabolic dysfunction-associated steatohepatitis (mash) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment: By Drug; By Therapy
2) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-User
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
Subsegments:
1) By Drug: Antifibrotic Agents; Antidiabetic Drugs; Lipid-Lowering Agents; Vitamin E; Obeticholic Acid (OCA); GLP-1 Agonists; Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy; Lifestyle Modifications (Dietary Changes, Exercise); Bariatric Surgery; Liver Transplantation
Companies Mentioned:Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Sanofi SA; AstraZeneca PLC
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33806

1. Executive Summary

2. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Characteristics

3. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Trends And Strategies

4. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth Rate Analysis
5.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Total Addressable Market (TAM)

6. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Segmentation

6.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
By Drug
By Therapy
6.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Homecare
Other End-User
6.3. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
6.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antifibrotic Agents
Antidiabetic Drugs
Lipid-Lowering Agents
Vitamin E
Obeticholic Acid (OCA)
GLP-1 Agonists
Other Drugs (Anti-Inflammatory Agents)
6.5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmacotherapy
Lifestyle Modifications (Dietary Changes, Exercise)
Bariatric Surgery
Liver Transplantation

7. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Regional And Country Analysis

7.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

8.1. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

9.1. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
9.2. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

10.1. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

11.1. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
11.2. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

12.1. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

13.1. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

14.1. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
14.2. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

15.1. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
15.2. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

16.1. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

17.1. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

18.1. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

19.1. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

20.1. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

21.1. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
21.2. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

22.1. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

23.1. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
23.2. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

24.1. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
24.2. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

25.1. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
25.2. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

26.1. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
26.2. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

27.1. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

28.1. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
28.2. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

29.1. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
29.2. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape And Company Profiles

30.1. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape
30.2. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Eli Lilly and Company
31.3. Gilead Sciences Inc.
31.4. Boehringer Ingelheim International GmbH
31.5. Novo Nordisk A/S
31.6. Apollo Health and Lifestyle Limited
31.7. Jenny Craig
31.8. Celerion
31.9. Nutrisystem
31.10. Madrigal Pharmaceuticals
31.11. Anoos Clinic
- 31.12. 89 Bio
31.13. Biosynth
31.14. DiogenX
31.15. Galectin Therapeutics Inc.

32. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

34. Recent Developments In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

35. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market High Potential Countries, Segments and Strategies

35.1 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Countries Offering Most New Opportunities
35.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Segments Offering Most New Opportunities
35.3 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer